Filing summary
Entity note: Although the request metadata names Sonoma Pharmaceuticals, the supplied Form 10-Q is for Oculus Innovative Sciences, Inc. (now described in the filing as a specialty pharmaceutical company). The filing covers the quarter and six months ended September 30, 2016, in its fiscal year ending March 31, 2017. Financial amounts below are in U.S. dollars; statement amounts are generally in thousands.
Business context and reporting period
Oculus develops and markets products for dermatology and advanced tissue care, including prescription dermatology products in the United States and Microcyn-branded products internationally. It reported results for the three- and six-month periods ended September 30, 2016, compared with the same periods in 2015. The statements are unaudited. A 1-for-5 reverse stock split took effect June 24, 2016; reported share and per-share figures were retrospectively adjusted.
Key financial metrics
| Metric | Three months ended Sept. 30, 2016 | Six months ended Sept. 30, 2016 | Comparable 2015 period |
|---|---|---|---|
| Total revenue | $4.108 million | $7.919 million | $4.054 million; $7.734 million |
| Gross profit / margin | $2.082 million / 51% | $4.001 million / 51% | $2.090 million / 52%; $3.963 million / 51% |
| Operating expenses | $4.022 million | $8.512 million | $3.948 million; $8.132 million |
| Operating loss | $1.940 million | $4.511 million | $1.858 million; $4.169 million |
| Net loss | $1.949 million; $0.46 per share | $4.517 million; $1.08 per share | $1.763 million; $0.54 per share; $4.103 million; $1.30 per share |
| Operating cash flow | Not separately presented | $(4.001) million | $(4.333) million |
For the six months, product revenue rose 16% to $7.318 million, while product licensing fees and royalties fell 81% to $150,000 and service revenue declined to $451,000. U.S. product revenue increased 56% to $3.070 million; Latin American product revenue decreased 19% to $2.290 million. Product gross margin improved to 52% from 49%, which management attributed mainly to a higher mix of higher-margin dermatology products.
Cash and cash equivalents were $3.254 million at September 30, down from $7.469 million at March 31, 2016. Working capital was $5.240 million, compared with $9.337 million. Total debt was approximately $78,000 ($28,000 current and $50,000 long-term). The company reported an accumulated deficit of $156.892 million. No dividends or material off-balance-sheet arrangements were reported in the supplied text.
Material changes and unusual items
- Six-month revenue increased 2%, but net loss widened by $414,000, primarily reflecting a $380,000 increase in operating expenses. Selling, general and administrative expense rose 7% to $7.773 million; research and development expense fell 16% to $739,000.
- Revenue growth in product sales was offset by steep declines in licensing and royalty revenue, including lower amortization of upfront payments from Laboratorios Sanfer and the loss of revenue from former partners Exeltis and Innovacyn.
- On October 27, 2016, after the reporting date, Oculus completed a sale of certain Latin American assets to Invekra for stated consideration of $22 million: $18 million paid at closing, $1.5 million held in escrow subject to delivery obligations, and $2.5 million payable in Mexican currency over ten years for services and technical assistance. The future payments are subject to currency fluctuation and sales-related terms.
- Oculus expects the transaction to significantly reduce Latin American revenue and total revenue in the near term. It expects royalties of 3% on qualifying Latin American net sales outside Mexico, with a stated minimum of $250,000 annually for ten years, paid in Mexican pesos. The company will supply products during a transition as Invekra establishes manufacturing; the transition duration is uncertain. A supply interruption lasting six consecutive months could trigger a penalty initially capped at $2 million, declining over the supply term.
- Oculus recorded $817,000 of stock-based compensation for the six-month period. A termination agreement with a sales contractor included $111,000 of cash fees, 14,390 shares valued at $62,000, and transfer of assets valued at $62,000; the filing records the related expense in SG&A.
Outlook, liquidity, and risks
Management said cash, including proceeds from the Invekra sale, was expected to fund working capital and continued sales, marketing, and research and development for at least 12 months from the filing date. The company nevertheless expected continued losses and said it might need additional capital to fund product development and market expansion. Management planned to use sale proceeds to expand its U.S. dermatology sales force, develop and launch products, and support working capital. It expected SG&A to rise as sales territories and personnel are added and described the planned Lasercyn launch within the next three months.
Key risks include replacing revenue lost from Latin America, successfully growing U.S. dermatology sales, executing the transition supply and equipment-delivery obligations, foreign-exchange exposure on peso payments, customer concentration, and the possibility of needing additional financing. One customer accounted for 29% of six-month revenue; at period-end, five customers represented 44%, 17%, 14%, 14%, and 13% of net receivables. The company also adopted a Section 382 rights agreement in October 2016 to help protect its ability to use tax-loss carryforwards; an ownership change could substantially limit their use. Management reported disclosure controls were effective as of September 30, 2016.
Most important facts for investors to verify
- Confirm the issuer identity: the supplied filing is Oculus Innovative Sciences, not Sonoma Pharmaceuticals.
- Review the Invekra asset purchase agreement for escrow release conditions, the ten-year payment and royalty mechanics, supply commitments, penalties, and required equipment and technology costs, which the filing said were not yet accurately estimable.
- Assess whether U.S. dermatology growth can offset the expected reduction in Latin American revenue, and track post-sale revenue, margins, and cash use.
- Verify liquidity and financing needs against continued operating losses, the stated 12-month runway estimate, and future capital requirements.
- Monitor customer concentration, peso exchange-rate exposure, and the potential effect of ownership changes on tax-loss carryforwards.